Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/191786
Title: | A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets |
Author: | Herzog, Chiara Marín, Fátima Jones, Allison Evans, Iona Reisel, Daniel Redl, Elisa Schreiberhuber, Lena Paytubi Casabona, Sònia Pelegrina, Beatriz Carmona, Álvaro Peremiquel Trillas, Paula Frias Gomez, Jon Pineda, Marta Brunet, Joan Ponce, Jordi Matias-Guiu, Xavier Sanjosé, Silvia de Alemany, Laia Olaitan, Adeola Wong, Michael Jurkovic, Davor Crosbie, Emma J. Rosenthal, Adam N. Bjørge, Line Zikan, Michal Dostalek, Lukas Cibula, David Sundström, Karin Dillner, Joakim Costas, Laura Widschwendter, Martin |
Keywords: | Càncer d'endometri Epigenètica Endometrial cancer Epigenetics |
Issue Date: | 20-Nov-2022 |
Publisher: | American Society of Clinical Oncology (ASCO) |
Abstract: | Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival.METHODSWe developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86).RESULTSWe describe the Women's cancer risk IDentification - quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology.CONCLUSIONThe WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits. |
Note: | Reproducció del document publicat a: https://doi.org/10.1200/JCO.22.00266 |
It is part of: | Journal of Clinical Oncology, 2022, vol. 40, issue. 33, p. 3828-3838 |
URI: | http://hdl.handle.net/2445/191786 |
Related resource: | https://doi.org/10.1200/JCO.22.00266 |
ISSN: | 1527-7755 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jco.22.00266.pdf | 877.58 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License